0001209191-21-005547.txt : 20210126 0001209191-21-005547.hdr.sgml : 20210126 20210126202401 ACCESSION NUMBER: 0001209191-21-005547 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210124 FILED AS OF DATE: 20210126 DATE AS OF CHANGE: 20210126 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Macrae Sandy CENTRAL INDEX KEY: 0001675687 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30171 FILM NUMBER: 21556387 MAIL ADDRESS: STREET 1: 721 ST. GEORGES ROAD CITY: PHILADELPHIA STATE: PA ZIP: 19119 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC CENTRAL INDEX KEY: 0001001233 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 680359556 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7000 MARINA BLVD CITY: BRISBANE STATE: CA ZIP: 94005 BUSINESS PHONE: 5109706000 MAIL ADDRESS: STREET 1: 7000 MARINA BLVD CITY: BRISBANE STATE: CA ZIP: 94005 FORMER COMPANY: FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC DATE OF NAME CHANGE: 20000208 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-01-24 0 0001001233 SANGAMO THERAPEUTICS, INC SGMO 0001675687 Macrae Sandy C/O SANGAMO THERAPEAUTICS, INC. 7000 MARINA BLVD BRISBANE CA 94005 1 1 0 0 President and CEO Common Stock 2021-01-24 4 F 0 3977 14.95 D 244002 D Represents shares of common stock underlying the portion of the restricted stock unit ("RSU") grant surrendered by the Reporting Person to the Issuer for tax withholding upon settlement of such RSU grant on January 24, 2021, using the Issuer's closing stock price on January 22, 2021 of $14.95/share, pursuant to the terms of the Issuer's 2013 Stock Incentive Plan. Includes 6,523 shares common stock issued on January 24, 2021 upon settlement of Reporting Person's January 24, 2018 RSU grant. Additionally this amount includes: 42,168 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on February 25, 2019, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended"); and 168,750 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on February 25, 2020 pursuant to the terms of the Issuer's Amended and Restated 2018 EIP, as amended. All such RSUs vest with respect to 1/3rd of the shares in each respective RSU grant in three equal annual installments over the three-year period measured from the dates of grant, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended. /s/ Matthew Colvin, Attorney-in-Fact for Sandy Macrae 2021-01-26